The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases
Open accessAbstract
Background and aims Causes of inflammatory bowel diseases are not well understood and the most prominent forms Crohn’s disease (CD) and ulcerative colitis (UC) are sometimes hard to distinguish. Glycosylation of immunoglobulin G (IgG) has been associated with CD and UC. IgG Fc-glycosylation affects IgG effector functions. We evaluated changes in IgG Fc-glycosylation associated with UC and CD, as well as with disease characteristics in different patient groups. Methods We analyzed 3441 plasma samples, obtained from 2 independent cohorts of patients with CD (874 patients in Italy and 391 in the United States [US]) or UC (1056 in Italy and 253 in the US and healthy individuals (controls) (427 in Italy and 440 in the US). IgG Fc-glycosylation (tryptic glycopeptides) was analyzed by liquid chromatography coupled to mass spectrometry. We analyzed associations between disease status (UC vs controls, CD vs controls, and UC vs CD) and glycopeptide traits, and associations between clinical characteristics and glycopeptide traits, using a logistic regression model with age and sex included as covariates. Results Patients with CD or UC had lower levels of IgG galactosylation than controls. For example, the odds ratio (OR) for IgG1 galactosylation in patients with CD was 0.59 (95% CI, 0.51–0.69) and for patients with UC was 0.81 (95% CI, 0.71–0.92). Fucosylation of IgG was increased in patients with CD vs controls (for IgG1: OR, 1.27; 95% CI, 1.12–1.44) but decreased in patients with UC vs controls (for IgG23: OR, 0.72; 95% CI, 0.63–0.82). Decreased galactosylation associated with more severe CD or UC, including the need for surgery in patients with UC vs controls (for IgG1: OR, 0.69; 95% CI, 0.54–0.89) and in patients with CD vs controls (for IgG23: OR, 0.78; 95% CI, 0.66–0.91). Conclusion In a retrospective analysis of plasma samples from patients with CD or UC, we associated levels of IgG Fc-glycosylation with disease (compared to controls) and its clinical features. These findings could increase our understanding of mechanisms of CD and UC pathogenesis and be used to develop diagnostics or guide treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adjusting batch effects in microarray expression data using empirical Bayes methods
Johnson, W. E., Li, C., & Rabinovic, A. (2007) · Biostatistics · doi:10.1093/biostatistics/kxj037 · Cited by 8,658
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
The International IBD Genetics Consortium (IIBDGC), Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Philip Schumm, L., Sharma, Y., et al. (2012) · Nature · doi:10.1038/nature11582 · Cited by 4,722
Self-citationUnravelling the pathogenesis of inflammatory bowel disease
Xavier, R. J., & Podolsky, D. K. (2007) · Nature · doi:10.1038/nature06005 · Cited by 4,364
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Burisch, J., Pedersen, N., Čuković-Čavka, S., Brinar, M., Kaimakliotis, I., Duricova, D., Shonová, O., Vind, I., Avnstrøm, S., Thorsgaard, N., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-304636 · Cited by 429 · cited 3×
“Abbreviations A2 diantennary A2B structures with bisecting β(1,4) N-acetylglucosamine A2F fucosylated structures A2FB structures with bisecting β(1,4) N-acetylglucosamine on IgG4 ADCC antibody-dependent cellular cytotoxicity”
BackgroundSelf-citationGlycans Are a Novel Biomarker of Chronological and Biological Ages
Krištić, J., Vučković, F., Menni, C., Klarić, L., Keser, T., Beceheli, I., Pučić-Baković, M., Novokmet, M., Mangino, M., Thaqi, K., et al. (2014) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glt190 · Cited by 400
Self-citationFerrara, C., Brünker, P., Suter, T., Moser, S., Püntener, U., & Umaña, P. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20777 · Cited by 305
Lee, J. C., Biasci, D., Roberts, R., Gearry, R. B., Mansfield, J. C., Ahmad, T., Prescott, N. J., Satsangi, J., Wilson, D. C., Jostins, L., et al. (2017) · Nature Genetics · doi:10.1038/ng.3755 · Cited by 304
In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity
Thomann, M., Schlothauer, T., Dashivets, T., Malik, S., Avenal, C., Bulau, P., Rüger, P., & Reusch, D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0134949 · Cited by 220
Mechanisms of disease: The human N-glycome
Lauc, G., Pezer, M., Rudan, I., & Campbell, H. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.10.016 · Cited by 184
Self-citationTranscriptional risk scores link GWAS to eQTLs and predict complications in Crohn's disease
Marigorta, U. M., Denson, L. A., Hyams, J. S., Mondal, K., Prince, J., Walters, T. D., Griffiths, A., Noe, J. D., Crandall, W. V., Rosh, J. R., et al. (2017) · Nature Genetics · doi:10.1038/ng.3936 · Cited by 166
Self-citation
Cited by
Glycosylation in health and disease
Reily, C., Stewart, T. J., Renfrow, M. B., & Novak, J. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0129-4 · Cited by 2,075
Glycosylation: mechanisms, biological functions and clinical implications
He, M., Zhou, X., & Wang, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01886-1 · Cited by 499
Immunoglobulin G glycosylation in aging and diseases
Gudelj, I., Lauc, G., & Pezer, M. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.07.009 · Cited by 408
Self-citationDiversity and dynamism of IgA−microbiota interactions
Huus, K. E., Petersen, C., & Finlay, B. B. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00506-1 · Cited by 198
The immune interactions of gut glycans and microbiota in health and disease
(2024) · doi:10.1111/mmi.15267 · Cited by 14
Metadata
- Authors
- Šimurina, M., de Haan, N., Vučković, F., Kennedy, N. A., Štambuk, J., Falck, D., Trbojević-Akmačić, I., Clerc, F., Razdorov, G., Khon, A., Latiano, A., D'Incà, R., Danese, S., Targan, S., Landers, C., Dubinsky, M., Campbell, H., Zoldoš, V., Permberton, I. K., Kolarich, D., Fernandes, D. L., Theorodorou, E., Merrick, V., Spencer, D. I., Gardner, R. A., Doran, R., Shubhakar, A., Boyapati, R., Rudan, I., Lionetti, P., Krištić, J., Novokmet, M., Pučić-Baković, M., Gornik, O., Andriulli, A., Cantoro, L., Sturniolo, G., Fiorino, G., Manetti, N., Arnott, I. D., Noble, C. L., Lees, C. W., Shand, A. G., Ho, G.-T., Dunlop, M. G., Murphy, L., Gibson, J., Evenden, L., Wrobel, N., Gilchrist, T., Fawkes, A., Kammeijer, G. S. M., Vojta, A., Samaržija, I., Markulin, D., Klasić, M., Dobrinić, P., Aulchenko, Y., van den Heuve, T., Jonkers, D., Pierik, M., McGovern, D. P. B., Annese, V., Wuhrer, M., & Lauc, G.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2018-04
- Volume
- 154
- Issue
- 5
- Pages
- 1320-1333.e10
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2782199578
- Cited by
- 167
- References
- 12
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.